Bionovo Announces 2008 Highlights and Year-End Financial Results
... to the Endocrine Society indicating that estrogen
receptor beta may have a role in cancer ... describing the structural elucidation of active estrogen
receptor beta selective compounds from VG101, ... well provide superior efficacy and safety versus estrogen
Full Year Result ...
Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
... therapy for hot flashes."
"Menerba is an estrogen
receptor beta selective drug," said Jan Ake
Gustafsson, M.D., the discoverer of estrogen
receptor beta, from Houston
University and a ... first Phase 2 clinical trial support the role of estrogen
beta as a novel target for treating ...
Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform
... of specific tissue effect.
modulators (SERMs) are an exciting class of drugs ... regulation in various tissues by each estrogen
provides a new platform for the ... Bionovo.
"The discovery of these selective estrogen
regulatory elements strengthens
our SERM ...
Azur Pharma Ltd. Enters Into Definitive Agreement With BioSante Pharmaceuticals Inc [nasdaq: BPAX], to Acquire U.S. Rights to Elestrin (TM)
Azur will market Elestrin to estrogen
prescribing physicians in the U.S.,
comprised ... practitioners
who write the majority of estrogen
prescriptions. Azur is in an excellent
position to capture an important share of the U.S. estrogen
which is currently estimated at ...
Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
... DX in 44 percent of patients with node-
receptor-positive breast cancer.
"The results ... to administer
chemotherapy in node-negative estrogen
receptor-positive breast cancer
patients should ... of 85
consecutive patients with node-negative, estrogen
cancer who had used the ...
Bionovo Develops a High Throughput LC-MS/MS Method for Simultaneous Quantification of Multiple Bioactive Compounds
... regulatory process."
MF101 is an estrogen
receptor beta (ER-b) selective drug, developed ... of breast and uterine cancers is associated
receptor alpha (ER-a) activation and that estrogen
beta (ER-b) blocks the growth promoting ...
Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
... focus exclusively on women with
levels -- a group whose survival is ... show the important relationship
between levels of estrogen
and XYOTAX' effectiveness in lung cancer. ... women with advanced NSCLC who
have pre-menopausal estrogen
levels (>30pg/mL). The phase III trial ...
Ethan Weiss, M.D., Joins Bionovo's Scientific Advisory Board
... His work is critical to the clotting
safety elucidation of Bionovo's estrogen
receptor beta selective drugs."
Dr. Weiss added, "Our results, so far, ... of sex differences
in blood clotting and to define the mechanisms whereby estrogen
the risk of clotting.
Bionovo is a ...
Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress
... DX reports by including quantitative HER2 scores; quantitative estrogen
receptor and progesterone receptor scores were added earlier this ... DX changed treatment recommendations in 44 percent of node- negative, estrogen
receptor-positive breast cancer patients. -- Presented results from two ...
Retrospective Analysis of Phase 3 Data Suggest Wyeth's Investigational Compound Bazedoxifene/Conjugated Estrogens Comparable to Placebo on Incidence of Abnormal Mammograms
... osteoporosis. Wyeth
describes this compound as a tissue selective estrogen
In a retrospective analysis of data from another phase 3 ... symptoms.
Wyeth describes the pairing of a selective estrogen
(SERM) and one or more estrogens as a TSEC. The TSEC ...
Bionovo Reports Second Quarter 2008 Financial Results
... through the
mitochondrial pathway, and induces cell death only in estrogen
negative breast cancer cells. BN108 induces cancer cell death by ... in a number of studies that have further
elucidated the mechanisms of the estrogen
receptor beta pathway, which are
the basis of the Company's MF101 and ...
Genomic Health Announces Expansion of Oncotype DX(R) Breast Cancer Test to Include Quantitative Estrogen Receptor (ER) and Progesterone Receptor (PR) Scores
... Oncotype DX can
deliver quantitative gene expression levels for assessing estrogen
(ER) and progesterone receptor (PR) status, which are critical ... into their treatment planning.
"Every breast tumor expresses the estrogen
receptor gene at a specific
level and, similar to other diagnostic ...
Genomic Health Announces First Quarter 2008 Financial Results and Business Progress
... reports by providing quantitative measurements of gene expression for estrogen
and progesterone receptors.
Reimbursement for Oncotype DX -- ... to include the majority of women diagnosed with node-negative, estrogen
receptor-positive breast cancer.
International -- Established ...
deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor-Positive Breast Cancer
... on chromosome 5 of the human genome that are
associated with risk of estrogen
receptor-positive (ER+) breast cancer.
More than 60% of the general ... classified as ER+ or ER-
according to whether tumors are found to contain estrogen
women of European descent approximately three-quarters are ...
Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness
... will describe the isolation and identification of a natural,
receptor (ER) beta compound from VG101 and three
synthetic derivatives. ... and unlike currently available hormone
therapies, does not activate the estrogen
receptor alpha, known to be
implicated in tumor formation. Phase 1/2 ...
Stonegate Report About Unigene Laboratories Inc.
... of calcitonin-based
products - Bisphosphonate therapies and selective estrogen
modulators (SERMS) are the current market leaders in the ... calcium, vitamin D, testosterone,
parathyroid hormone and selective estrogen
receptor modulators (SERMs). The
results indicated that bisphosphonates ...
Bio-Identical Hormone Menopause Doctor Responds to Outrageous FDA News
... to their news release, the FDA does not approve of the use of
estriol in any compounded formula. They consider this the
manufacture of ... would certainly like the FDA to reconsider the
published evidence on this estrogen
and change their ruling," comments Dr.
Because of the misleading ...
Sanofi-aventis Announces Second Quarter 2009 Results
... product in association with chemotherapy in women with metastatic triple negative breast cancer (mTNBC), i.e. with a tumor that expresses neither the estrogen
receptor nor the progesterone receptor and does not over-express the HER2 receptor.
Enrolment to the Phase III study, evaluating NV1FGF in ...
Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer
... breast cancer treatment planning and selection in Europe.
According to the guidelines, the threshold for recommending chemotherapy in treating estrogen
receptor (ER) positive, HER2-negative breast cancer is difficult to define. Clinical research in the United States and other countries shows that ...
Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
... to enroll more than 900 patients at approximately 180 sites in over 30 countries - including North America, Europe, Asia and Australia. Patients with estrogen
receptor-positive and/or progesterone receptor-positive, non-resectable locally advanced, recurrent or metastatic breast cancer receiving hormonal ...
Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
regulation of fatty acids and cholesterol supports a role of lipid
homeostasis in schizophrenia.
NR1-092 Selective estrogen
receptor modulators share the
antipsychotic gene expression profile, suggesting their potential in the
treatment of schizophrenia.
Ausio Pharmaceuticals to Present at Bio(R) 2009
... and Phase 1 Clinical Results
AUS-131 is pure, synthetic S-equol, a soy metabolite, and acts as a nonsteroidal, nonhormonal, selective estrogen
receptor beta (ER beta) agonist. The safety profile of AUS-131 in FDA-required preclinical studies was excellent, and AUS-131 has demonstrated ...
Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
... at the 2009 USCAP ( United States and Canadian Academy of Pathology ) meeting demonstrated that the expression of FOXA1, now known to be an estrogen
receptor associated transcription factor, correlated with Oncotype Dx(R) when performed in patient samples from Indiana University . In this ...
New Analysis Finds Bioidentical Hormones Safer Than Standard Hormone Replacement Therapy
... of pregnant horse hormones that are not found in the human body or synthetic hormones that have physiologic effects that mimic or mirror the natural estrogen
or progesterone effects in the body. In contrast, bioidentical hormone replacement contains molecules that are exact replicas of the endogenous ...
Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
... Dr. Dhingra joined Eli Lilly and Company as Clinical Research Physician with responsibility for the global development strategy of a novel Selective estrogen
Receptor Modulator. In 1999, he joined Hoffmann-La Roche as Clinical Science Leader. Over the next nine years Dr. Dhingra assumed positions of ...
Bert W. O'Malley, M.D., Recipient of the 2008 National Medal for Science, Joins Bionovo's Scientific Advisory Board
... of reproductive tissue growth and
development by steroid hormones, and provided the foundation for all future
regulatory studies of the impact of estrogen
and progesterone on implantation
of a fertilized egg, pregnancy maintenance, and prenatal embryonic
development, and for the hormone mediated ...
Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance
... that GRB7-dependent pathways are
potential therapeutic targets for triple-negative breast cancer, a
subtype that does not express estrogen
receptor (ER), progesterone
receptor (PR) or HER2 genes.
- Study results demonstrating that quantitative RT-PCR analysis is
Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
... newly patented method uses cMyc-ER, a recombinant fusion of two proteins normally present in cells, c-Myc, a human cell-cycle regulating protein, and estrogen
receptor (ER), a human protein that is activated by estrogen. By transiently increasing the concentration of the c-Myc protein, a cell inserted with ...
Bionovo to Present Recent Findings of BN107, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium
... the ability of BN107 to induce cancer
cell death is distinct. BN107 induces apoptosis through the mitochondrial
pathway. BN107 induces death only in estrogen
receptor negative breast cancer
cells. Our studies show that cholesterol depletion and disruption of lipid
raft-mediated signaling is most likely ...
Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
... Poster presentation (Poster Session III: Tumor Cell and Molecular
Biology: Hormonal Factors and Receptors): "Associations between
receptor (ER) Alpha expression levels and ER genotypes"
Presenter: Daniel Hayes, M.D., University of Michigan Health System,
FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
... and/or oral diabetes
medicines, drugs metabolized by the liver (for example, corticosteroids,
sex steroids, anticonvulsants, cyclosporine), or oral estrogen
Adult height can be influenced if you are on Norditropin(R) for growth
failure and at the same time using glucocorticoids or thyroid ...
Breast Cancer Patients Take DNA Test to Determine Best Treatment
... shows that tamoxifen has to be activated into endoxifen
by the liver enzyme CYP2D6. Endoxifen is the medicine that prevents the
recurrence of estrogen
receptive positive cancers.
About ten percent of breast cancer patients prescribed tamoxifen are
missing CYP2D6 because of their DNA, and will fail ...
James L. Wittliff, Ph.D., FACB, to Present 'Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System' at the Association for Molecular Pathology Conference, October 30
... order to identify clinically relevant molecular signatures."
Dr. Wittliff was among the first investigators to prove that the
expression of estrogen
receptors in breast cancer predicted a patient's
response to hormone therapy. This finding led to collaborations with the
National Surgical Adjuvant ...
deCODE genetics Announces Second Quarter 2008 Financial Results
... -- Diagnostics: Breast cancer. In the second quarter deCODE discovered
a fourth set of common single-letter variants (SNPs) associated with risk
receptor-positive (ER+) breast cancer. Although these variants
confer modest risk, they are so common that they are estimated to account
Ipsogen Launches MapQuant Dx(TM) Genomic Grade Test to Identify Breast Cancer Patients who Benefit From Chemotherapy
... grade to improve prognosis.
J Natl Cancer Inst. 2006 Feb 15;98(4):262-72.
(2) Loi S et al. Definition of clinically distinct molecular subtypes
receptor-positive breast carcinomas through genomic grade. J
Clin Oncol. 2007 Apr 1;25(10):1239-46.
(3) Symmans WF et al. Use of genomic grade ...
Bionovo Reports First Quarter 2008 Financial Results
... of Cancer Research (AACR) conference in April. BN107 induces apoptosis through the mitochondrial pathway, and induces cell death only in estrogen
receptor negative breast cancer cells. BN108 induces cancer cell death by rapid inactivation of both AKT and mTOR pathways in breast cancer ...
deCODE genetics Announces First Quarter 2008 Financial Results
-- Diagnostics: Breast cancer. In April, deCODE published its discovery of the fourth set of common SNPs associated with risk of estrogen
receptor-positive (ER+) breast cancer. The latest SNPs are on chromosome 5p12, and although these variants confer modest risk, they are ...
JCI table of contents: April 22, 2008
... BIOLOGY: How is a regulator of sex hormone production regulated itself?
The production of the sex hormones testosterone, progesterone, and estrogen
is controlled by two other hormones, which are known as luteinizing hormone (LH) and follicle stimulating hormone (FSH). Disturbances in the levels ...
Ortho Evra Patch Makers Settling Cases
... Ortho-McNeil, one of the manufacturers of Ortho Evra,
admitted for the first time that women who use the patch will be exposed to
up to 60% more estrogen
than those taking a birth control pill with 35
micrograms of estrogen. The patch is only intended to deliver 20 micrograms
It is ...
Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research
... death cancer cell death is distinct from that of BN108. BN107
induces apoptosis through the mitochondrial pathway. BN107 induces death
only in estrogen
receptor negative breast cancer cells. BN108 induces
cancer cell death by rapid inactivation of both AKT and mTOR pathways in
breast cancer cells, ...